{
    "root": "35bc5d7a-4115-4fd4-e063-6394a90a4f20",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Zolpidem",
    "value": "20250522",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 102",
            "code": "PNR0YF693Y"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "ZOLPIDEM TARTRATE",
            "code": "WY6W63843K"
        }
    ],
    "indications": "zolpidem tartrate tablets indicated short-term treatment insomnia characterized difficulties sleep initiation . zolpidem tartrate tablets shown decrease sleep latency 35 days controlled [ ( 14 ) ] . trials performed support efficacy 4–5 weeks duration final formal assessments sleep latency performed end treatment .",
    "contraindications": "lowest dose effective patient must exceed total 10 mg daily ( 2.1 ) treatment short possible ( 2.1 ) recommended initial dose single dose 5 mg women single dose 5 10 mg men , immediately bedtime least 7-8 hours remaining planned time awakening ( 2.1 ) geriatric patients patients mild moderate hepatic impairment : recommended dose 5 mg men women ( 2.2 ) lower doses cns depressants may necessary taken concomitantly zolpidem tartrate tablets ( 2.3 ) effect zolpidem tartrate tablets may slowed taken immediately meal ( 2.4 )",
    "warningsAndPrecautions": "zolpidem tartrate tablets , usp 5 mg pink film coated , round biconvex tab lets , debossed `` 117 `` one side , side plain supplied : ndc number size 51407-877-30 bottle 30 51407-877-01 bottle 100 51407-877-10 bottle 1000 zolpidem tartrate tablets , usp 10 mg white film coated , round biconvex tab lets , debossed `` 118 `` one side , side plain supplied : ndc number size 51407-878-30 bottle 30 51407-878-01 bottle 100 51407-878-10 bottle 1000 store controlled room temperature 20°c-25°c ( 68°f-77°f ) .",
    "adverseReactions": "zolpidem tartrate tablets contraindicated patients experienced complex sleep behaviors taking zolpidem tartrate tablets [ ( 5.1 ) ] known hypersensitivity zolpidem . observed include anaphylaxis angioedema [ ( 5.4 ) ]",
    "indications_original": "Zolpidem Tartrate Tablets is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem Tartrate Tablets has been shown to decrease sleep latency for up to 35 days in controlled clinical studies\n \n  [see Clinical Studies (\n  \n   14)].\n \n  \n                  \n                  The clinical trials performed in support of efficacy were 4–5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.",
    "contraindications_original": "Use the lowest dose effective for the patient and must not exceed a total of 10 mg daily ( 2.1 ) Treatment should be as short as possible ( 2.1 ) Recommended initial dose is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening ( 2.1 ) Geriatric patients and patients with mild to moderate hepatic impairment: Recommended dose is 5 mg for men and women ( 2.2 ) Lower doses of CNS depressants may be necessary when taken concomitantly with Zolpidem Tartrate Tablets ( 2.3 ) The effect of Zolpidem Tartrate Tablets may be slowed if taken with or immediately after a meal ( 2.4 )",
    "warningsAndPrecautions_original": "Zolpidem Tartrate Tablets, USP 5 mg is pink film coated, round biconvex tab lets, debossed \"IT 117\" on one side, other side is plain and supplied as:\n                  \n                     \n                        NDC Number\n                     \n                     \n                        Size\n                     \n                  \n                  51407-877-30 bottle of 30\n                  51407-877-01 bottle of 100\n                  51407-877-10 bottle of 1000\n                  Zolpidem Tartrate Tablets, USP 10 mg is white film coated, round biconvex tab lets, debossed \"IT 118\" on one side, other side is plain and supplied as:\n                  \n                     \n                        NDC Number\n                     \n                     \n                        Size\n                     \n                  \n                  51407-878-30 bottle of 30\n                  51407-878-01 bottle of 100\n                  51407-878-10 bottle of 1000\n                  Store at controlled room temperature 20°C-25°C (68°F-77°F).",
    "adverseReactions_original": "Zolpidem Tartrate Tablets is contraindicated in patients\n                  \n                     who have experienced complex sleep behaviors after taking Zolpidem Tartrate Tablets\n  \n   [see Warnings and Precautions (\n   \n    5.1)]\n  \n   \n                     \n                     with known hypersensitivity to zolpidem. Observed reactions include anaphylaxis and angioedema\n  \n   [see Warnings and Precautions (\n   \n    5.4)]"
}